Dr Reddy’s Laboratories announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the US Food and Drug Administration (USFDA).
Capecitabine tablet is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:
- Adjuvant Colon Cancer
– Patients with Dukes’ C colon cancer
- Metastatic Colorectal Cancer
– First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred
- Metastatic Breast Cancer
– In combination with docetaxel after failure of prior anthracycline-containing therapy
– As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen
The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.
Dr Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.